NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) posted its quarterly earnings results on Friday, November, 1st. The company reported $0.91 EPS for the quarter, topping the Zacks' consensus estimate of $0.83 by $0.08. The company had revenue of $888.70 million for the quarter, compared to analysts' expectations of $876.20 million. MEDNAX had a positive return on equity of 10.38% and a negative net margin of 40.86%. The firm's revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for MEDNAX.

MEDNAX updated its fourth quarter earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $0.87-0.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.93.

11 analysts have issued 12 month price targets for MEDNAX's shares. Their forecasts range from $18.00 to $34.00. On average, they expect MEDNAX's stock price to reach $27.73 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

News headlines about MD stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEDNAX earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for MEDNAX.

MEDNAX saw a decrease in short interest in December. As of December 31st, there was short interest totalling 6,370,000 shares, a decrease of 6.2% from the December 15th total of 6,790,000 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is currently 5.4 days. Approximately 7.9% of the shares of the company are sold short. View MEDNAX's Current Options Chain.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Chevron (CVX), Dominion Energy (D), Walt Disney (DIS), Gilead Sciences (GILD), Intel (INTC), AbbVie (ABBV), CVS Health (CVS), General Electric (GE), UnitedHealth Group (UNH) and Exxon Mobil (XOM).

MEDNAX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Triad Investment Management (0.07%), Sage Capital Advisors llc (0.07%), Nisa Investment Advisors LLC (0.06%), Wedge Capital Management L L P NC (0.02%), State of Alaska Department of Revenue (0.02%) and Altfest L J & Co. Inc. (0.01%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including Triad Investment Management and State of Alaska Department of Revenue. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, FNY Investment Advisers LLC, Wedge Capital Management L L P NC, Sage Capital Advisors llc and Altfest L J & Co. Inc.. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $27.69.

MEDNAX has a market capitalization of $2.33 billion and generates $3.65 billion in revenue each year. The company earns $268.62 million in net income (profit) each year or $3.51 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]